Twist Bioscience
Twist Bioscience has developed a semiconductor-based synthetic DNA manufacturing process capable of producing synthetic biology tools, including genes, oligonucleotide pools and variant libraries.
In April 2014, the US company announced the acquisition of Genome Compiler Corporation, an Isreali-based company providing software for genentic engineers, molecular and synthetic biologists, to strengthen its position as the technology leader in DNA synthesis.
It provides synthetic genes used in research and development by many of the leading names in big pharma around the world.
Latest Twist Bioscience News & Features
31 August 2023
10 February 2022
17 December 2021
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze